20cm速递｜科创创新药ETF国泰（589720）收跌，连续10日净流入近5亿元，行业需求复苏与结构升级趋势明显，回调或可布局

Group 1 - The core viewpoint of the article highlights a recovery in industry demand and a clear trend of structural upgrades within the innovative pharmaceutical sector, suggesting potential investment opportunities despite a recent decline in the ETF [1] - The ETF tracking the innovative pharmaceutical index has seen a net inflow of nearly 500 million yuan over the past 10 days, indicating strong investor interest [1] - The report emphasizes the strong performance expectations for WuXi AppTec and similar companies, showcasing the growth momentum in the CXO sector, which is expected to continue benefiting from a recovering investment climate in the innovative drug industry [1] Group 2 - The article notes that the innovative pharmaceutical ETF (GTJA, 589720) tracks the innovative drug index (950161), which includes listed companies engaged in drug research and development, covering various fields such as biopharmaceuticals, chemical drugs, and traditional Chinese medicine [1] - The investment focus should shift towards the clinical value of pharmaceuticals, addressing clinical needs of patients, which is expected to command a higher premium in both domestic and global markets [1] - The report expresses optimism for the innovative drug supply chain and innovative medical devices, particularly high-end medical equipment and high-value consumables, as part of the ongoing structural upgrades in the industry [1]